Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data.

Current opinion in drug discovery & development, 2008 - europepmc.org
Efavirenz non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy or boosted
protease inhibitor (PI)-based therapy are currently recommended as first-line regimens for …

Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data

ZK Sweeney, K Klumpp - Current opinion in drug …, 2008 - pubmed.ncbi.nlm.nih.gov
Efavirenz non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy or boosted
protease inhibitor (PI)-based therapy are currently recommended as first-line regimens for …